DBV Technologies reported positive top‑line results from the Vitesse Phase 3 trial: the Viaskin peanut epicutaneous patch met its primary endpoint in children aged 4–7, with a treatment responder rate roughly 47% versus 15% for placebo after 12 months. The company plans a Biologics License Application (BLA) submission in the first half of next year. Viaskin delivers small amounts of peanut antigen through the skin to induce desensitization; the trial showed statistically significant protection and mostly mild‑to‑moderate local skin reactions as the most common adverse events. Two treatment‑related anaphylaxis events were reported and managed. DBV’s result follows earlier regulatory setbacks and a multi‑year development effort; a successful BLA could reopen an FDA pathway for a non‑invasive food‑allergy immunotherapy option for young children.